Peptide Vaccine Against Strep Throat Bacteria Protects Mice Against Multiple Bacterial Strains | Research

The takeaway

A C-terminal peptide from the M12 protein of group A Streptococcus showed cross-serotype protection in mice, with antibodies capable of killing M1, M3, M6, and M18 strains — offering hope for a broadly protective strep vaccine.

Cross-protection against 4 additional serotypes
M12-C antiserum opsonized and killed M1, M3, M6, and M18 GAS strains despite being raised against a single M12 peptide, demonstrating the broad protective potential needed for a practical strep vaccine

What the researchers found

The M12-C peptide vaccine candidate showed multiple advantages: shortened vaccination schedule, enhanced antibody levels, and improved survival against both vaccine-type and non-vaccine-type streptococcal strains. M12-C antiserum demonstrated opsonization and killing of multiple non-vaccine strains (M1, M3, M6, M18). All three vaccine candidates induced Th1-type responses with IFN-γ secretion and increased effector memory T cells.

Why it matters

Group A Streptococcus causes millions of infections annually with no approved vaccine. A peptide-based approach that protects across multiple serotypes could finally enable a broadly effective GAS vaccine.

The numbers in context

M12-N: 28.14 kDa; M12-C: 30.24 kDa; M12-N+C: 29.19 kDa; Cross-reactive against M1, M3, M6, M18 serotypes

How the study worked

Three fusion peptide constructs (M12-N, M12-C, M12-N+C) derived from the M12 protein were expressed with a KSI tag and formulated with aluminum hydroxide adjuvant. Mice were immunized and evaluated for antibody titers, survival after subcutaneous challenge with homologous (MGAS9429) and heterologous (MGAS5005) strains, T cell responses, and opsonophagocytic killing of multiple GAS serotypes.

What this study cannot tell us

Preclinical mouse study — human immune responses to M protein peptides may differ and carry autoimmune risks (rheumatic fever/heart disease). Cross-reactivity with human cardiac tissue was not assessed. Only a limited number of GAS serotypes were tested for cross-protection. Long-term safety data is lacking. The aluminum hydroxide adjuvant used may not be optimal for clinical development.

How to read the evidence

This is a preclinical vaccine study in mice with comprehensive immunological characterization including antibody titers, survival challenges, T cell analysis, and opsonophagocytic killing assays. While thorough, human translation faces significant hurdles, particularly autoimmune safety concerns.

When this study was published

Published in 2025, this study contributes to the active global effort to develop a GAS vaccine, with several candidates from different groups currently in clinical trials.

The bigger picture

A GAS vaccine has been a major public health goal for decades — the bacterium causes over 500,000 deaths annually worldwide, primarily from rheumatic heart disease in developing countries. The M protein is the most promising vaccine target but has been hindered by autoimmune concerns (M protein shares sequences with human heart tissue). This study's approach — using carefully selected M protein peptide fragments — aims to generate protective immunity while avoiding the dangerous autoimmune cross-reactivity. The demonstration of cross-serotype protection addresses another key barrier to GAS vaccine development.

Questions still open

Does the M12-C peptide vaccine avoid cross-reactivity with human cardiac tissue, which is the main safety concern for M protein-based GAS vaccines?
Could M12-C be combined with peptides from other M types to create a broadly protective multivalent vaccine?
Would the cross-serotype protection hold against the most common GAS strains circulating in high-burden regions?

Common questions

Why don't we have a vaccine for strep throat?

Group A Streptococcus has over 200 different types, and the main surface protein (M protein) varies between them. Additionally, some M protein sequences look similar to human heart tissue, raising concerns that a vaccine could accidentally trigger rheumatic heart disease. Researchers have spent decades trying to find peptide fragments of the M protein that protect against infection without causing autoimmune reactions — which is exactly what this study is working toward.

Why is cross-serotype protection important?

For a strep vaccine to be practical, it needs to protect against many different GAS types — not just one. This study showed that a single peptide from the M12 protein generated antibodies capable of killing four additional types (M1, M3, M6, M18). This kind of broad protection is essential for a vaccine that would work worldwide, where different strep types dominate in different regions.

Read the original research

Immunization with the M12-N, M12-C, and M12-N+C fusion peptides derived from the M12 protein elicited varying levels of protective immune responses against multiple serotypes of group A Streptococcus.

Frontiers in immunology, 16, 1636591

View on PubMed ↗Publisher’s paper ↗

Citation

Zhang, Xiaolan; Ma, Yue; Na, Rige; Hou, Wenli; Hanski, Emanuel; Zhou, Qin. (2025). Immunization with the M12-N, M12-C, and M12-N+C fusion peptides derived from the M12 protein elicited varying levels of protective immune responses against multiple serotypes of group A Streptococcus.. Frontiers in immunology, 16, 1636591. https://doi.org/10.3389/fimmu.2025.1636591